Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to evaluate the effect of proton pump inhibitors on the regional composition of the gut microbiota and metabolic profiles of health volunteers using the CapScan collection capsule.
Prospective, open-label, single-arm, non-randomized, single-center study designed to evaluate the effect of proton pump inhibitors on the regional composition of the gut microbiota and metabolic profiles of health volunteers using the CapScan collection capsule.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CapScan | Device | Gut sampling capsule |
| Measure | Description | Time Frame |
|---|---|---|
| Identification of the gut microbial taxa using DNA sequencing of the samples obtained from the CapScan devices | A primary endpoint is to identify and quantitate the relative abundance of the gut microbial taxa using at least 3 million metagenomic DNA sequencing reads in at least 75% of the samples obtained from the CapScan devices. | 2 months |
| Identification of the gut metabolites using liquid chromatography - mass spectrometry of the samples obtained from the CapScan devices | A primary endpoint is to identify at least 1,500 annotated gut metabolites from the intestinal tract in at least 75% of the samples obtained from the CapScan devices. | 2 months |
| Measure | Description | Time Frame |
|---|---|---|
| Detect changes in composition of gut microbial taxa using DNA sequencing in subjects before and after omeprazole treatment | Evaluate the diversity, centroids and distributions of microbial taxa from sequenced CapScan samples of the study population from before and after omeprazole treatment. | 2 months |
| Detect changes in composition of gut metabolites using liquid chromatography - mass spectrometry in subjects before and after omeprazole treatment |
Not provided
INCLUSION CRITERIA
Subjects must meet all of the following criteria to be included in the study:
EXCLUSION CRITERIA
Subjects with any of the following conditions or characteristics must be excluded from the study:
History of any of the following:
Daily PPI use in the last 30 days
Pregnancy or planned pregnancy within 30 days from Screening Visit, or breast-feeding
Any form of active substance abuse or dependence (including drug or alcohol abuse), unstable medical or psychiatric disorder, or any chronic condition susceptible, in the opinion of the investigator, to interfere with the conduct of the study
A clinical condition that, in the judgment of the investigator, could potentially pose a health risk to the subject while involved in the study
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jennifer Taufui | Contact | 650-988-7530 | svgistaff@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Silicon Valley Gastroenterology | Mountain View | California | 94040 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluate the diversity, centroids and distributions of gut metabolites in CapScan samples of the study population from before and after omeprazole treatment. |
| 2 months |